A Stage 2/3, Adaptive, Randomized, Controlled, Double-blind Study to Investigate the Pharmacokinetics, Efficacy and Safety of the Hyperimmune Equine Serum (INM005) in Adult Patients With Moderate to Severe Confirmed SARS-CoV2 Disease
Latest Information Update: 02 Nov 2021
At a glance
- Drugs INM-005 (Primary)
- Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease
- Focus Registrational; Therapeutic Use
- Sponsors Inmunova
- 08 Feb 2021 Status changed from active, no longer recruiting to completed.
- 27 Oct 2020 Planned End Date changed from 1 Nov 2020 to 1 Dec 2020.
- 27 Oct 2020 Planned primary completion date changed from 1 Oct 2020 to 23 Nov 2020.